Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mark J. Axelrod"'
Autor:
Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Publikováno v:
Blood Advances, Vol 1, Iss 14, Pp 933-946 (2017)
Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable response
Externí odkaz:
https://doaj.org/article/8971b2c6746d4ca78045d1f18e8e94de
Autor:
Brian J Capaldo, Devin Roller, Mark J Axelrod, Alex F Koeppel, Emanuel F Petricoin, Craig L Slingluff, Michael J Weber, Aaron J Mackey, Daniel Gioeli, Stefan Bekiranov
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138210 (2015)
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms
Externí odkaz:
https://doaj.org/article/961cab1c45ad41c99b460cd723f70e2f
Autor:
Qin Liu, Aaron R. Goldman, Mark J. Axelrod, Zayas-Bazan D, Lipchick B, Zachary T. Schug, Subhasree Basu, Hsin-Yi Chen, Patricia Reyes-Uribe, Michael J. Weber, Jessie Villanueva, Yiling Lu, GB Mills, Adam N. Guterres, Andrew V. Kossenkov, Maureen E. Murphy, Xiangfan Yin, David W. Speicher
SUMMARYAlthough oncogenic NRAS activates MAPK signaling, inhibition of the MAPK pathway is not therapeutically efficacious in NRAS-mutant tumors. Here we report that silencing the ribosomal protein S6 kinase 2 (S6K2), while preserving the activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e26a1ad9817cf3535fe98f69f3c1b80
https://doi.org/10.1101/2021.04.07.438684
https://doi.org/10.1101/2021.04.07.438684
Autor:
Stefan Bekiranov, Timothy P. Bender, Julia Wulfkuhle, Emanuel F. Petricoin, Michael J. Weber, Mark J. Axelrod, Vicki L. Gordon, Kallesh Danappa Jayappa, Michael E. Williams, Rosa I. Gallagher, Brian J. Capaldo, L. Kyle Brett, Craig A. Portell
Publikováno v:
Blood Advances. 1:933-946
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To iden
Autor:
Abel P. David, Stephen S. Schoeff, Mark J. Jameson, Patrick O. McGarey, Lane Donaldson, Ashraf Khalil, Rolando E. Mendez, Henry F. Frierson, Julia Wulfkuhle, Mark J. Axelrod, Christine E. Lehman, Edward B. Stelow, Linnea E. Taniguchi, Matthew A. Hubbard, Stefan Bekiranov, Daniel Gioeli, Emanuel F. Petricoin, Michael I. Dougherty
Publikováno v:
The LaryngoscopeBIBLIOGRAPHY. 130(6)
Objectives The insulin-like growth factor-1 receptor (IGF1R) has been implicated in therapeutic resistance in head and neck squamous cell carcinoma (HNSCC), and small molecule tyrosine kinase inhibitors (TKIs) of IGF1R activity may have anticancer ac
Autor:
Mark R. Conaway, Stephanie Leimgruber, Elizabeth R. Sharlow, Mark J. Jameson, Ashraf Khalil, Rolando E. Mendez, Michael J. Weber, Brian J. Capaldo, Mark J. Axelrod, Daniel Gioeli
Publikováno v:
Head & Neck. 37:1722-1732
Background. In head and neck squamous cell carcinoma (HNSCC), resistance to single-agent targeted therapy may be overcome by co-targeting of compensatory signaling pathways. Methods. A targeted drug screen with 120 combinations was used on 9 HNSCC ce
Autor:
Elyse Lopez, M L Wang, Richard J. Ford, Archito T. Tamayo, Mark J. Axelrod, Michael J. Weber, Laura Kyle Brett, Liang Zhang, Vicki L. Gordon, Michael E. Williams, Zhishuo Ou, L V Pham
Publikováno v:
Leukemia
Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma
Autor:
Daniel J. Neitzke, Daniel Gioeli, Adel Tarcsafalvi, Mark J. Axelrod, Michael J. Weber, Vicki L. Gordon, Mark R. Conaway
Publikováno v:
Oncotarget
// Mark Axelrod 1 , Vicki L. Gordon 1 , Mark Conaway 2 , Adel Tarcsafalvi 1,3 , Daniel J. Neitzke 1,4 , Daniel Gioeli 1 , and Michael J. Weber 1 1 Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, USA
Autor:
Michael J. Weber, Brian J. Capaldo, Mark J. Axelrod, Karin Jensen, Aaron J. Mackey, Devin G. Roller, Daniel Gioeli
Publikováno v:
Molecular Cancer Therapeutics. 11:2505-2515
Recent data show that extracellular signals are transmitted through a network of proteins rather than hierarchical signaling pathways, suggesting that the inhibition of a single component of a canonical pathway is insufficient for the treatment of ca
Autor:
Mark J. Axelrod, Patricia Reyes-Uribe, Andrew V. Kossenkov, Michael J. Weber, Gordon B. Mills, Minu Samanta, Hsin-Yi Chen, Qin Liu, Yiling Lu, Xiangfan Yin, Jessie Villanueva
Publikováno v:
Cancer Research. 78:2381-2381
Oncogenes often upregulate nutrient sensing and utilizing pathways, leading to altered metabolism in tumor cells. RAS-driven tumors typify cancers undergoing marked metabolic reprogramming. In melanoma, RAS signaling is often deregulated; while activ